Christopher Peetz, Chief Executive Officer and Director of Mirum Pharmaceuticals, Inc., filed a Form 4 on November 4, 2026, disclosing the exercise of a fully vested stock option and a same-day sale of common stock pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Peetz acquired 20,000 shares of common stock on November 4, 2026, via an employee stock option with an exercise price of $2.936 per share.
  • Shares sold: 20,000 shares of common stock were disposed of on November 4, 2026, at a price of $90 per share, according to the filing.
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 plan adopted by Peetz on March 2, 2026.
  • Direct ownership after transactions: Peetz directly held 206,637 shares of common stock following the reported transactions.
  • Indirect ownership: An additional 187,500 shares are held indirectly by The Peetz Family Trust.
  • Remaining options: Following the exercise, Peetz held 38,487 employee stock options with an exercise price of $2.936, expiring March 11, 2029.

Christopher Peetz's November 2026 Transactions at Mirum Pharmaceuticals

According to the Form 4 filed with the SEC, Christopher Peetz, who serves as Chief Executive Officer and Director of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), reported two transactions in Table I on November 4, 2026. The first was an acquisition of 20,000 shares of common stock coded "M," reflecting the exercise of an employee stock option at a per-share price of $2.936. Following that acquisition, the filing shows Peetz directly owned 226,637 shares.

The second transaction was a disposition coded "S," covering 20,000 shares at a price of $90 per share. The filing states in footnote 1 that this sale "occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026." After this sale, the filing reports Peetz's direct beneficial ownership stood at 206,637 shares. Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company whose common stock trades on NASDAQ under the symbol MIRM.

In Table II, the filing discloses that the employee stock option exercised on November 4, 2026, was fully vested, carried an exercise price of $2.936, and had an expiration date of March 11, 2029. The option covered 20,000 shares of common stock, and the price of the derivative security at exercise is listed as $0. Following the exercise, Peetz retained 38,487 employee stock options. The filing was signed by Judit Ryvkin as Attorney-in-Fact on November 4, 2026, and indicates the form was filed by one reporting person.

What Was Disclosed

The Form 4 filed on November 4, 2026, by Mirum Pharmaceuticals CEO Christopher Peetz reported the exercise of a fully vested stock option covering 20,000 shares at $2.936 per share and the same-day sale of 20,000 shares at $90 per share under a pre-adopted 10b5-1 plan, leaving him with 206,637 directly held shares and 187,500 shares held through The Peetz Family Trust.